Showing results (121-130 of 160) with videos related to
Sort By:
Pageof 16
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.Cancer Cell|October 22, 2020
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT ExperienceAnnalisa Trama, Claudia Proto, Jennifer G Whisenant, et al.The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.Therapeutic Advances in Medical Oncology|June 12, 2025
NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignanciesJoan R Choo, Santhiay Nathan Jeraj, Raghav Sundar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung CancerAlice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerEng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2019
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLCWan Ling Tan, Kevin L M Chua, Chia-Chi Lin, et al.Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.NPJ Precision Oncology|November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian populationJing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.Pageof 16